Month: February 2014

The tetrasubstitued peptide CJC-1295 No DAC has a chemical structure of C₁₅₂H₂₅₂N₄₄O₄₂ and a molecular weight of 3367.2.  Its structure is that of a 30 amino acid peptide chain.  Its functionality is marked by its ability to bioconjugate with the globular protein serum albumin; this means that contains an ability to pair up two biomolecules in order to form a chemical bond.

CJC-1295 No DAC’s Relationship with GHRH1-29

According to scientific study that has been based on animal test subjects, it has been determined that CJC-1295 No DAC’s overall functionality and mechanics has been linked to an active agent found within the peptide chain GHRH1-29.

Basically, GHRH1-29 is a prime component of the negative feedback loop that is located within the growth hormone axis of animal test subjects.  This process essentially acts as a means of regulatory control over a host of endocrine system-related processes, thus enabling an animal test subject the ability to maintain a consistent level of homeostasis.

The main issue with GHRH1-29 is that its inherent properties are not long lasting.  This is due to the fact that it has a very rapid half-life; one that lasts less than seven minutes.  The culprit behind this extremely short half-life is an enzyme known as dipeptidyl amino peptidase IV, or DPP-IV.  This particular peptide functions by stimulating the production of antibodies and is essentially associated with processes tied to immune system regulation, signal transduction, and apoptosis (that is, programmed cell death).  Because of the way in which DPP-IV functions, the enzyme more or less causes GHRH1-29’s half-life to cease rather quickly.

However, CJC-1295 No DAC’s relationship with GHRH1-29 essentially subdues DPP-IV’s half-life terminating effects, thus allowing GHRH1-29 to experience an uptick in bioavailability as well as a dramatic increase in half-life – one that lasts for over seven days.  This extension enables the growth hormone axis within an animal test subject to experience a greater interval of production, which in turn allows the animal test subject to experience a more efficient means of homeostasis.  This process is also linked to a few other aspects of CJC-1295 No DAC’s functionality, including its ability to block methionine oxidation and lower levels of deconstruction relating to the amino acid asparangine.

CJC-1295 No DAC’s Functionality and Boosted Processes

According to scientific study that has been built around animal test subjects, it has been determined that CJC-1295 No DAC and its relationship with GHRH1-29 can be linked to several elevated processes.  Some of these boosted processes include:

• Elevated protein synthesis – scientific study on animal test subjects has determined that CJC-1295 No DAC’s ability to extend the half-life of GHRH1-29 and therefore allow for a greater functionality regarding the growth hormone axis in animal test subjects has led to the thought that a longer interval of cellular receptor engagement can occur, which in turn can cause more proteins to be produced.
• A reduction of adipose tissue, or body fat – CJC-1295 No DAC’s overall mechanics has demonstrated a capacity to promote the process in which lipids are broken down.  Because of this accelerated degradation of lipids, it has been determined that body fat can be burned through on a significantly more efficient basis.
• An elevation in the growth of muscular tissue – Because it has been determined that CJC-1295 No DAC can produce an increased proliferation of proteins, scientific study based on animal test subjects has determined that the peptide can influence a greater influx of muscle cells.  This then leads to an increase in muscle mass and size amongst animal test subjects.
• An expedited recovery from injury – CJC-1295 No DAC’s ability to boost protein synthesis is also thought to enable animal test subjects to heal from various injuries on a more efficient basis.
• An improved instance of deep sleep – Scientific study based on animal test subjects have determined that the process of protein synthesis reaches its apex when the test subject experiences its deepest level of sleep.  Because of this, it is thought that an animal test subject will be able to experience an enhanced measure of deep sleep as a means to provide compensation for the elevated process of protein synthesis.
• Boosted bone density – Scientific study based on animal test subjects has determined that CJC-1295 No DAC enables an increased measure of generation regarding bone mineral manner per square centimeter.  This in turn allows for stronger bones that are less susceptible to fractures, breaks, and other bone-related issues.

All matters of research relating to the way in which CJC-1295 No DAC operates has all been culled from scientific study on animal test subjects.  Because of this, any observations relating to CJC-1295 No DAC’s overall functionality should exclusively be the product of study performed in a strictly contained environment such as a medical research facility or a laboratory.

PDF View/Download

The tetrasubstitued peptide CJC 1295 with DAC has a molecular formula of C₁₅₂H₂₅₂N₄₄O₄₂, and a molecular weight of 3368.7.  Its structural integrity is composed of 30 amino acids.  Its overall functionality has been marked by its ability to bioconjugate with the globular protein serum albumin, which in turn leads to an advanced level of homeostasis within an animal test subject.

The Interactions with CJC 1295 with DAC

According to scientific study that has been based on animal test subjects, it has been determined that CJC 1295 with DAC’s inherent functionality hinges on its interaction with two specific components that are found within an animal test subject’s body:

• GHRH1-29 – this peptide chain is responsible for regulating the activity of the growth hormone axis of an animal test subject.  Its release is part of a process referred to as a negative feedback loop.
• DPP-IV – Otherwise known as dipeptidyl amino peptidase IV, this antigenic enzyme is chiefly associated with processes related to immune system regulation, programmed cellular death, and signal transduction.  Its process has been shown to cause GHRH1-29 to experience a rapid half-life that lasts under seven minutes.

It has been shown through scientific study on animal test subjects that CJC 1295 with DAC essentially quells the production of DPP-IV from happening.  This in turn enables it to allow GHRH1-29 to experience a dramatic increase in its half-life; one that allows it to last over seven days.  This elevated stabilization causes the growth hormone axis to experience a greater level of operation, thus enabling an animal test subject to experience a greater level of homeostasis.

Additionally, scientific study based on animal test subjects has determined that CJC 1295 with DAC’s functionality allows it to block methionine oxidation.  This is important to note because this process is considered to be a key factor in contributing to an animal test subject’s aging process.

CJC 1295 with DAC and Elevated Processes

Because it has been shown that CJC 1295 with DAC has the ability to extend the stability and half-life of GHRH1-29 and block the production of DPP-IV, scientific study that has been conducted on animal test subjects has determined that its presence could be at the root of several elevated processes that a test subject may be able to experience.

The biggest of these elevated process ties to an overall elevation in protein synthesis.  Because CJC 1295 with DAC’s functionality essentially causes a greater capacity of function for an animal test subject’s growth hormone axis, it has been determined that the test subject could process a greater amount of proteins over a longer period of time.  This extended process is thought to be a vital component of allowing an animal test subject to maintain an elevated state of homeostasis.  Most of the other benefits that have been built around it via scientific study on animal test subject all trace back to this overarching process.

• For example, this boost in protein synthesis has allowed scientific study based on animal test subjects to determine that it can increase the rate at which muscular tissue can be grown.  Because of the proliferation of proteins as brought about by protein synthesis, it has been determined that an animal test subject can experience an uptick in the level of muscle size and muscle mass over time.
• The added level of protein synthesis has been thought to play a vital role in boosting bone density.  Specifically, research based on animal test subjects has noted that the boost can cause a bone’s mineral matter per square centimeter to increase.  This then makes the bones of an animal test subject to be stronger and less vulnerable to breaks, fractures, and other bone-related injuries.
• The increase has also been shown to potentially play a key role in the reduction of adipose tissue; that is, body fat.  The overall mechanics of CJC 1295 with DAC has been shown to promote lipolysis; the process in which the lipids that eventually form body fat are broken down.  This accelerated degradation of lipids in turn enables the level of body fat to decrease.

It has also been thought that the elevation in protein synthesis can lead to a boosted amount of deep sleep.  The reasoning here is based on the determination that an animal test subject’s peak time of activity related to protein synthesis occurs during deep sleep.  As such, it is thought that the boost in protein synthesis can cause an elevated amount of deep sleep as a means of compensation.

Any findings or observations relating to CJC 1295 with DAC should exclusively be the product of study performed in a strictly contained environment.

PDF View/Download

BPC 157 is a pentadecapeptide, meaning that is comprised of a chain of 15 amino acids.  It has been determined to be a partial sequence of body protection compound (BPC) that can be isolated from gastric juices located in animal test subjects.  It possesses a molecular mass of 1419.53552, and its molecular formula is C₆₂H₉₈N₁₆O₂₂.  It can be referred to by the alternate names BPC 15, BPC-157, or Booly Protection Compound 15.

Properties of BPC 157

Because BPC 157 has proven to be isolated from gastric juices, it should not be a surprise to find that various scientific studies that have been conducted on animal test subjects have been able to pinpoint several links between the peptide’s presence and digestive tract functionality.  Specifically, it has been determined that BPC 157 exhibits the capacity to regulate and control the manner in which the digestive tract can operate.  One of the ways that BPC 157 accomplishes this is through safeguarding the endothelium, which is the thin layer of cells that line the blood vessels’ interior surface.  Another way the peptide carries out regulatory function is by being a key factor in the process of angiogenesis; that is, the process in which new blood vessels are formed from pre-existing blood vessels.  This latter process is further bolstered by BPC 157’s ability to form granulation tissue; this term references the new connective tissues and tiny blood vessels that develop on the surface of wound, thus making the peptide an important piece to the overall wound healing process.  Further studies have also shown that the peptide’s inherent functionality allows it to contain anti-inflammatory properties.  Additionally, these studies have determined that BPC 157 can also help in the regulation and control of blood flow throughout an animal test subject’s gastro-intestinal tract.

BPC 157’s Anti-Inflammatory Properties

The anti-inflammatory qualities that BPC 157 has been shown to contain has enabled scientific study that has been conducted on animal test subjects to derive several ways in which the peptide plays a vital role in combating inflammatory concerns throughout the gastro-intestinal tract.

One of the primary roles that the peptide could conceivably play is in relation to reducing the effects of conditions that are tied to inflammatory bowel disease; a group of complex vascular tissue responses that center on the small intestine and the colon.  Some of the more prominent conditions in this regard include:

• Ulcerative Colitis – A disease of the colon that is marked by characteristic ulcers or open sores.
• Chron’s Disease – A chronic inflammatory disorder that is caused by interactions between various factors pertaining to bacteria, the environment, and the immune system.

Another key condition in which BPC 157 is said to lessen is esophagitis.  This potentially serious condition is marked by the inflammation of the esophagus.  This act of inflammation could make the rudimentary process of swallowing difficult.

Several negative processes involving the gingival, or gums, has also been shown to be somewhat quelled by the inherent properties of BPC 157.  Scientific study that has been conducted on lab rats has determined that the peptide exhibits an ability to lower the instance of fluid leakage that may occur around the teeth as a result of area inflammation.  What’s more, the peptide has also been shown to reduce a process known as alveolar bone resorption, meaning that there is a lower instance of calcium being released from bone fluid and entering the bloodstream.  These studies also show that these processes occur without any blood circulation alteration in healthy gingival.

BPC 157 and Wound Healing

Additional scientific study that has been based on animal test subjects has determined that BPC 157’s processes relating to angiogenesis enable it to elevate the level in which a wound can be repaired.  Studies that have been built around rat Achilles tendons that were cut transversely have shown that the presence of the peptide greatly accelerated the outgrowth of tendon explants.  Furthermore, these studies have determined that the presence of the peptide can also promote cellular survival in various scenarios built around wound-based trauma.

The current use of the peptide is solely intended for scientific research purposes and nothing more.  Any findings or observations relating to BPC 157’s overall functionality the determinations that can be derived from such observations should be exclusively contained to a strictly controlled environment such as a laboratory or a medical research facility.

PDF View/Download